AEGON LTD. (AEG): what the price assumes

Generated: 2026-07-24 · Exported: 2026-07-25 · Source: https://boothcheck.com/report/AEG

Headline

Field	Value
Ticker	AEG
Company	AEGON LTD.
Sector / Industry	Financial Services
Current price	$9.14/sh

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Field	Value
Inversion basis	financials
Return on equity needed	11.8%
Return on equity now	10.4%
ROE gap	+1.4pp
Price-to-book	1.32x

Solve inputs: computed at a 9.9% cost of equity with 4% terminal growth over a 5-year stage, on common book equity (FY2025); each 1pp of cost of equity moves the implied ROE ~1.3pp.

How unusual the bet is: within-range

Reference	Value
vs own history	+1.71σ
cohort percentile (of 89 peers)	34
sustained it ~10 years at this level	70%
implied end-window share	0%

Valuation X-Ray

The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Family	Median price/FV	Models	Reads
Asset	1.17x	3	expensive
Earnings	0.88x	2	justifies
Relative	0.41x	3	justifies
Growth	0.62x	1	justifies

Families that justify the price: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 5.0%); the inversion above states its own rate.

Per-Model Detail (n=9)

Model	Family	FV	Price/FV	Applicable	Methodology
DCF Perpetual Growth	Growth	—	—	no	—
Bank Fair Value (P/TBV)	—	$8.05	1.13x	yes	TBVPS $6.43 × 1.25x (ROE (TTM) 10.3% / CoE 9.3%, g=5.0% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption))
Relative Valuation	Relative	$7.05	1.30x	yes	P/E 11x (static sector reference · 2026-04), scenarios: 9.3x / 11.0x / 12.6x (bear / base = reference held flat / bull), EV/EBITDA 10x
Simple DDM	Growth	—	—	no	—
Two-Stage DDM	Growth	$14.79	0.62x	yes	Stage 1: 20% for 5yr, Stage 2: 3.5% perpetual
Simple Excess Return	Asset	$7.42	1.23x	yes	BV/sh $6.65, ROE (TTM) 10.3%, ke 9.3%
Two-Stage Excess Return	Asset	$7.82	1.17x	yes	5yr excess ROE then converge to ke=9.3%
Discounted Future Market Cap	Growth	—	—	no	—
Peter Lynch Fair Value	Relative	$22.45	0.41x	yes	EPS $0.64, growth 35% (input: historical EPS growth), PEG=0.38 (Undervalued)
Margin Trajectory	Growth	—	—	no	—
Earnings Power Value	Earnings	—	—	no	—
Residual Income	Asset	—	—	no	—
Graham Number	Asset	$9.79	0.93x	yes	√(22.5 × EPS $0.64 × BVPS $6.65) — Graham's conservative floor
EV/EBITDA Relative	Relative	—	—	no	—
FCF Yield	Earnings	—	—	no	—
SBC-Adj FCF Yield	Earnings	—	—	no	—
Ben Graham Formula	Earnings	$20.69	0.44x	yes	EPS $0.64 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/B	Asset	—	—	no	—
P/Sales Sector	Relative	—	—	no	—
PEG Fair Value	Relative	$24.05	0.38x	yes	EPS $0.64 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings Yield	Earnings	$6.93	1.32x	yes	EPS $0.64 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations Multiple	Relative	—	—	no	—
Clinical Phase NPV	Growth	—	—	no	—
Merton	Asset	—	—	no	—
V5 Mechanical	—	—	—	no	—

Solvency

Field	Value
Share count CAGR (buyback)	-6.6%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

• Transamerica is now about 70% of the business, and the board has chosen New York for a future head office and Delaware for the legal seat, with the holding company due to be renamed Transamerica.

• Today's price assumes a sustained return on equity of about 11.8%, above the return on equity of roughly 10.4% the company has recently been earning, and closing that gap is the whole job.

• First-half results land on August 20, 2026, and the sale of the UK business to Standard Life is due to complete around the end of the year, which is when the cash for debt reduction and further buybacks actually arrives.

Bull Case

Something unusual is happening to a company most investors still file under "Dutch insurer." About 70% of the operations are now American, run under the Transamerica name, and in June the board picked New York for a future head office and Delaware for the legal seat, with the holding company due to be renamed Transamerica by the start of 2028. That is not a marketing decision. It is the last step of a long pruning: in April the UK arm went to Standard Life for GBP 2.0 billion, made up of a 15.3% shareholding in Standard Life plus GBP 0.75 billion in cash.

What is left compounds in a way that is easy to overlook. The share count has been falling about 6.6% a year since the end of 2021. That is not housekeeping. It is the reason book value per share keeps climbing in years when the reported result does not. The most recent programme, EUR 227 million, finished on June 30 after retiring almost 34 million shares at an average of EUR 6.68, and a EUR 200 million programme started the next day and runs to late December.

The underlying business had a good 2025 by its own yardsticks. Operating result rose 15% to EUR 1.7 billion, the net result rose 45% to EUR 980 million, and operating capital generation of EUR 1.3 billion cleared the EUR 1.2 billion target management had set for itself. Free cash flow of EUR 829 million landed close to the roughly EUR 800 million the company had guided to.

The American half is where the commercial momentum sits. Transamerica's strategic assets produced EUR 526 million of operating result in the second half alone, its agent network passed 95,000 licensed agents, and individual new life sales rose 30% on the year. At the same time the legacy block keeps shrinking: capital employed in Transamerica's financial assets fell to USD 2.7 billion against a USD 2.9 billion target for the year. Capital coming out of a run-off book and going into a business that writes new policies is the least glamorous form of value creation there is, and one of the more reliable.

The balance sheet enables the plan rather than constraining it. Group solvency ended 2025 at 184%, with EUR 1.3 billion of cash capital at the holding company. The UK sale is expected to cost about five points of that solvency ratio while adding EUR 1.1 billion to shareholders' equity and EUR 0.6 billion to the net result on a pro forma 2025 basis.

The bear's central point is fair: the market is already paying for a better return on capital than the company currently earns. But the arithmetic of this particular pivot is that the businesses being sold earn less than the one being kept, and the proceeds have been earmarked for debt reduction and buybacks rather than for a new adventure. A smaller, simpler, dollar-earning company with fewer shares outstanding does not need a heroic operating improvement to reach what the market is paying for. It needs the mix shift to work roughly as advertised.

Bear Case

Start with what the buyer is agreeing to. Today's price assumes a sustained return on equity of about 11.8%. The return on equity the company has actually been earning is about 10.4%, and that figure already flatters itself with a strong 2025. Among firms that have earned this kind of return, roughly seven in ten went on to hold it for a decade, so the assumption is not extravagant. It is simply above where the business sits today, and something has to close the distance.

Here is why a small gap matters more for an insurer than it would elsewhere. The shares change hands at about 1.3 times book value, and that multiple is not a verdict on expansion. It is arithmetic on the return. Pay above book and the wager is simply that the company earns more on its capital than that capital costs. If the return drifts back toward the high single digits instead of climbing, the multiple the market will pay for that book compresses toward one, and the price moves down to the book rather than the book moving up to the price.

The pivot that is supposed to close the gap is a project, not an event. The extraordinary general meeting to approve the move of the legal home is contemplated for the fourth quarter of 2026, the New York office is expected to open in mid-2027, and the whole thing is meant to be finished by the start of 2028. Eighteen months of tax, regulatory and shareholder process sits between the announcement and the outcome, during which management attention is finite and the operating businesses still have to perform.

The UK proceeds are also not what a headline number suggests. Of the GBP 2.0 billion, GBP 0.75 billion arrives as cash and the rest is a 15.3% shareholding in Standard Life that Aegon has agreed to lock up for as long as eighteen months after completion. Only the cash portion can be turned into debt reduction and buybacks on any near-term schedule, and the group solvency ratio takes about a five-point hit at the same time.

Then there is the recurring shape of life insurance reporting. In the second half of 2025 the operating result rose while the net result came in at EUR 375 million, because non-operating charges landed on it. The operating line is management's view of run-rate earnings; the reported line is where assumption changes, market movements and old blocks of business actually show up. A buyer paying above book for a life and retirement company is paying for reserve estimates set years ago on mortality, morbidity and policyholder behaviour, and the reported result is where those estimates get marked to reality.

Currency runs underneath all of it. The accounts are in euros while most of the earnings are dollars, so a US holder of these shares is carrying an insurance business and an exchange rate at the same time, and the translated figures move whether or not anything operational changed.

Finally, the market's own verdict deserves respect rather than dismissal. Compared with its peer group, this name sits in the cheaper half on price to book, and it has for a while. Complexity, a legacy American book, and a multi-year corporate reconstruction are exactly the sort of things that keep a discount in place. The bear case here is not that the shares are expensive against the standard methods, because most of them land at or above the price. It is that the return has to improve while the company rebuilds itself on another continent, and neither the improvement nor the rebuild is finished.

Valuation

At $9.14, the shares change hands at about 1.3 times book value, and that price carries one assumption above all others: a sustained return on equity of about 11.8%, against a return on equity of roughly 10.4% recently earned. For an insurer that is the whole valuation argument in a sentence. What the company earns on its capital sets what its book is worth, and everything else is detail.

The methods used to triangulate a business like this mostly land above where the shares trade. Book value plus profitability is the exception: the price sits about 17% above where those methods land, which is the arithmetic consequence of paying a premium to book for a return that has not yet reached what the premium implies. The earnings-power methods land about 12% higher than the price. Peer comparison and the dividend-discount approach land considerably above it, and they reach it by extrapolating the last few years of per-share earnings expansion, a good deal of which came from retiring shares rather than from earning more on the same capital. Take the spread as a whole and it says what the return assumption says: this is a value and asset-supported name, not a bet on expansion.

The concrete version of the requirement is small and stubborn. Rather more than a point of return on equity separates what the company earns from what today's price assumes. On a book this size that is not a rounding difference. It is the difference between a buyback that compounds book value per share and a buyback that merely offsets a return which does not clear its own cost of capital.

The balance-sheet frame for an insurer is regulatory capital and payout capacity, not coverage ratios, and on that frame the position is comfortable. Group solvency ended 2025 at 184% with EUR 1.3 billion of cash capital at the holding company, and EUR 1.1 billion went back to shareholders during the year through dividends and buybacks. The UK sale is expected to take about five points off the solvency ratio and add EUR 1.1 billion to shareholders' equity, with the cash portion directed at debt reduction and further repurchases. Management has also been working on the liability side, pricing USD 500 million of ten-year senior unsecured notes at a 5.625% coupon in April and tendering for five subordinated note series with EUR 380 million of notional in May.

The share count is the quiet variable in all of this. It has fallen about 6.6% a year since the end of 2021, and management has committed to keep going, with a EUR 200 million programme running to late December. A company retiring stock at that pace does not need the return on its capital to rise much for the per-share figures to move. It needs the return not to fall.

Catalysts

Three dates matter between now and the end of the year. First-half results are scheduled for August 20, 2026. The sale of the UK business to Standard Life is expected to complete around the end of 2026, subject to regulatory approvals, with the cash portion earmarked for debt reduction and buybacks. And an extraordinary general meeting is contemplated in the fourth quarter to vote on moving the company's legal home to the United States.

Running underneath those is the repurchase programme. The EUR 200 million buyback that began on July 1 is due to finish on December 23, and Aegon's largest shareholder agreed to participate pro rata, which holds its stake steady rather than letting it drift upward as the count shrinks. The previous EUR 227 million programme closed on June 30 with almost 34 million shares retired at an average of EUR 6.68.

Further out, what changes is the shape of the company rather than any single number. Will Fuller becomes president and chief operating officer on January 1, 2027, taking day-to-day responsibility for Transamerica, the international businesses and the asset manager; the New York office is expected to open in mid-2027; and the holding company is due to be renamed Transamerica and legally American by the start of 2028. For a business that reports in euros and earns mostly in dollars, that is rather more than a change of address.

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Aegon press release, June 17, 2026 · Aegon press releases, April 15 and May 22, 2026 · Aegon press release, April 15, 2026 · Aegon press release, July 1, 2026 · Aegon 2H 2025 results, February 2026 · Aegon press releases, April 30 and May 8, 2026 · Aegon investor calendar, May 22, 2026